Supernus Pharmaceuticals Net Profit Margin 2011-2024 | SUPN

Supernus Pharmaceuticals net profit margin from 2011 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.
Supernus Pharmaceuticals Net Profit Margin Historical Data
Date TTM Revenue TTM Net Income Net Margin
2024-06-30 $0.63B $0.01B 0.79%
2024-03-31 $0.60B $-0.02B -2.68%
2023-12-31 $0.61B $0.00B 0.16%
2023-09-30 $0.61B $0.03B 4.09%
2023-06-30 $0.63B $0.04B 6.78%
2023-03-31 $0.67B $0.05B 7.78%
2022-12-31 $0.67B $0.06B 9.15%
2022-09-30 $0.66B $0.04B 5.77%
2022-06-30 $0.63B $0.06B 9.21%
2022-03-31 $0.60B $0.07B 12.31%
2021-12-31 $0.58B $0.05B 9.33%
2021-09-30 $0.56B $0.08B 14.72%
2021-06-30 $0.57B $0.10B 17.69%
2021-03-31 $0.56B $0.11B 20.11%
2020-12-31 $0.52B $0.13B 24.57%
2020-09-30 $0.48B $0.13B 27.25%
2020-06-30 $0.42B $0.12B 28.07%
2020-03-31 $0.40B $0.12B 29.10%
2019-12-31 $0.39B $0.11B 28.83%
2019-09-30 $0.41B $0.11B 25.98%
2019-06-30 $0.41B $0.11B 25.67%
2019-03-31 $0.40B $0.10B 25.50%
2018-12-31 $0.41B $0.11B 27.14%
2018-09-30 $0.38B $0.10B 25.98%
2018-06-30 $0.36B $0.09B 24.30%
2018-03-31 $0.33B $0.07B 21.86%
2017-12-31 $0.30B $0.06B 18.87%
2017-09-30 $0.28B $0.06B 20.65%
2017-06-30 $0.25B $0.10B 40.71%
2017-03-31 $0.23B $0.10B 41.92%
2016-12-31 $0.22B $0.09B 42.33%
2016-09-30 $0.20B $0.08B 42.64%
2016-06-30 $0.18B $0.03B 14.53%
2016-03-31 $0.16B $0.02B 11.04%
2015-12-31 $0.15B $0.01B 9.46%
2015-09-30 $0.14B $0.01B 8.15%
2015-06-30 $0.12B $0.01B 4.20%
2015-03-31 $0.11B $0.01B 5.31%
2014-12-31 $0.09B $-0.01B -11.83%
2014-09-30 $0.07B $-0.04B -51.39%
2014-06-30 $0.05B $-0.06B -118.00%
2014-03-31 $0.02B $-0.09B -445.00%
2013-12-31 $0.01B $-0.09B -827.27%
2013-09-30 $0.00B $-0.08B -4150.00%
2013-06-30 $0.00B $-0.07B -7200.00%
2013-03-31 $0.00B $-0.06B -5500.00%
2012-12-31 $0.00B $-0.05B -4700.00%
2012-09-30 $0.00B $0.05B inf%
2012-06-30 $0.00B $0.05B inf%
2012-03-31 $0.00B $0.05B 5300.00%
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $1.872B $0.608B
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $20.902B 7.10
Dr Reddy's Laboratories (RDY) India $12.399B 18.57
BridgeBio Pharma (BBIO) United States $4.791B 0.00
Bausch Health Cos (BHC) Canada $3.597B 2.61
Amphastar Pharmaceuticals (AMPH) United States $2.469B 13.82
Taysha Gene Therapies (TSHA) United States $0.314B 51.00
Personalis (PSNL) United States $0.270B 0.00
Assembly Biosciences (ASMB) United States $0.107B 0.00
Acasti Pharma (GRCE) Canada $0.031B 0.00
Sol-Gel Technologies (SLGL) Israel $0.014B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00